Home > Compound List > Product Information
Hexafluronium_Molecular_structure_CAS_317-52-2)
Click picture or here to close

Hexafluronium

Catalog No. DB00941 Name DrugBank
CAS Number 317-52-2 Website http://www.ualberta.ca/
M. F. C36H42Br2N2 Telephone (780) 492-3111
M. W. 662.54008 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 817

SYNONYMS

IUPAC name
N-{6-[(9H-fluoren-9-yl)dimethylazaniumyl]hexyl}-N,N-dimethyl-9H-fluoren-9-aminium dibromide
IUPAC Traditional name
N-[6-(9H-fluoren-9-yldimethylaminio)hexyl]-N,N-dimethyl-9H-fluoren-9-aminium dibromide
Brand Name
Milaxen
Mylaxen
Synonyms
Hexafluorenium bromide
Hexafluronium bromide
Hexafluorenium

DATABASE IDS

CAS Number 317-52-2
PubChem SID 46507171
PubChem CID 9434

PROPERTIES

Hydrophobicity(logP) -0.06

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholinesterases.
Indication Used as an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations.
Pharmacology Hexafluronium bromide is a cholinesterase antagonist that can be used to prolong the relaxation effects of succinylcholine or suxamethonium chloride. Suxamethonium acts as a depolarizing muscle relaxant. It imitates the action of acetylcholine at the neuromuscular junction and is degraded by pseudocholinesterase, a plasma cholinesterase. The prolonged stimulation of the acetylcholine receptor results first in disorganized muscle contractions, then in profound relaxation. Cholinesterases catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. There are two types of cholinesterase acetylcholinesterase and pseuodocholinesterase. The first hydrolyses acetylcholine more quickly; the latter hydrolyses butyrylcholine and succinylcholine more quickly. An absence or mutation of the pseudocholinesterase enzyme leads to a medical condition known simply as pseudocholinesterase deficiency. This is a silent condition that only manifests itself when people who have the deficiency receive the muscle relaxants succinylcholine or mivacurium during a surgery.
Toxicity LD50 = 280 mg/kg (mouse, oral)
Affected Organisms
Humans and other mammals
External Links
Wikipedia

REFERENCES